Taken together, these findings demonstrate that VRK2 is a downstream target of the FBXL6-TKT-ROS-mTOR axis and facilitates FBXL6-mediated HCC tumorigenesis and metastasis. This evidence concerns the gene TKT and hepatocellular carcinoma.